Survival in systemic sclerosis associated pulmonary arterial hypertension in the current treatment era-results from a nationwide study.
Alper SariHasan SatışGizem AyanOrhan KüçükşahinUmut KalyoncuAli Aykut FidancıMustafa Okan AyvalıNaim AtaMustafa Mahir ÜlgüŞuayip BirinciAli AkdoğanPublished in: Clinical rheumatology (2024)
Compared to most of historical cohorts, higher survival rates for SSc-PAH were observed in this study. Early diagnosis of PAH may have contributed to these findings. The impact of immunosuppressive therapy on prognosis of SSc-PAH needs to be further investigated in prospective studies. Key Points • Early diagnosis is pivotal for better outcomes in SSc-PAH. • Implementation of PAH treatment guidelines in routine clinical practice is still poor and should be improved. • Effect of immunosuppressive therapies on disease course has to be defined in SSc-PAH.
Keyphrases
- systemic sclerosis
- pulmonary arterial hypertension
- clinical practice
- polycyclic aromatic hydrocarbons
- pulmonary hypertension
- pulmonary artery
- type diabetes
- metabolic syndrome
- skeletal muscle
- rheumatoid arthritis
- mass spectrometry
- mesenchymal stem cells
- high resolution
- combination therapy
- insulin resistance
- smoking cessation
- high speed